Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

Novo Nordisk and Eli Lilly (NYSE: LLY) have been sparring for control of the booming anti-obesity drug market. Despite Novo Nordisk breaking the market open with Ozempic, Lilly made up ground and ultimately surpassed Novo Nordisk in the U.S.The fight between these two GLP-1 stocks has now entered round two. Novo Nordisk's Wegovy pill received approval in December, making it the first GLP-1 pill for weight loss. Now, Eli Lilly has punched back with Foundayo (orforglipron), its newly approved GLP-1 pill that will be available starting April 6.But this is the first of a one-two punch from Eli Lilly that could cement the company atop the weight-loss drug market for the foreseeable future.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool